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The synaptic vesicular monoamine transporter (SVMT), alternatively vesicular monoamine transporter 2 (VMAT2), pumps cytosolic monoamines including dopamine, norepinephrine, serotonin, and histamine into synaptic vesicles, using the proton gradient maintained across the synaptic vesicular membrane. [1] [2] [3] It plays a central role in determining the amount of monoaminergic neurotransmitters packaged in a vesicle to be available for exocytotic release. 4 The transporter is a site of action of important drugs such as reserpine and tetrabenazine, both of which inhibit vesicular amine transport. Reserpine is a useful drug in the treatment of hypertension and schizophrenia; however, high dosages of reserpine frequently produce a syndrome resembling depressive disorder. 5 Several lines of evidence suggest the involvement of the SVMT in the psychostimulant action of amphetamines which induce monoamine efflux from vesicles, 6 resulting in an increased amount of cytoplasmic neurotransmitter, although the mechanism of action remains to be elucidated. The SVMT is also important for sequestering toxins. It modulates susceptibility to N-methyl-4-phenylpyridinium (MPP + ), the active metabolite of the neurotoxin N-methyl-1,2,3,6-tetrahydropyridine (MPTP) that induces Parkinsonism. 7, 8 Recent studies on mutant mice lacking the SVMT gene have provided interesting findings. Although homozygotes for the mutated type die shortly after birth, heterozygous mice are viable into adult life and display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. 9 Extracellular striatal dopamine levels, as well as K + -and amphetamine-evoked dopamine release, were diminished in heterozygous mice which showed a pronounced supersensitivity to the locomotor effects of apomorphine, cocaine, and amphetamine. 10 Thus altered functions of SVMT may be involved in the pathogenesis of several neuropsychiatric diseases, including schizophrenia, mood disorders, drug abuse, and Parkinson's disease.
Liu et al 11 and Erickson et al 12 investigated cDNAs encoding the SVMT in rat brain. Surratt et al 13 identified the human homolog, which shares 92% amino acid identity with the rat sequence. They also demonstrated a TaqI polymorphism. The human SVMT gene maps to 10q25. 13, 14 Takahashi and Uhl 15 clarified the genomic structure of the murine SVMT gene; however, that of human homolog is still unclear.
Persico et al 16 examined the TaqI RFLP polymorphism of the SVMT gene 13 for linkage analysis in 16 multiplex pedigrees with schizophrenia spectrum disorders. They obtained results excluding close linkage between the SVMT gene and schizophrenia spectrum disorders in their pedigrees. However, the lack of statistical power in linkage analysis to detect moderate or weak effect 17 leaves the possibility that genetic variation of the SVMT gene might have a risk-increasing effect on schizophrenia. The present study determined exon/intron boundaries of the human SVMT gene and performed mutational analysis for the exonic and Exonic and intronic sequences are described by upper and lower case letters, respectively. a Sizes for introns 2, 3, 9, 10, 13, and 14 were estimated from obtained PCR products, referring to molecular weight markers. DNA sequences for exons and neighboring introns have been registered to the GenBank database (accession AB044395-AB044401).
neighboring intronic regions in which polymorphisms, if any, might be related to altered gene functions. Then we performed a family-based association analysis between schizophrenia and detected polymorphisms of the SVMT gene in a Japanese sample. Table 1 shows exon/intron boundaries of the human SVMT gene. All the boundaries were consistent with the GT/AG rule. Furthermore, the positions of inser- We found two single nucleotide polymorphisms (SNPs) at codons 68 in exon 3 and 199 in exon 5; neither SNP results in an amino acid change (Thr68Thr and Ser 199Ser). Furthermore, we detected four SNPs in the neighboring introns: one in intron 6, two in intron 7, and the other in intron 14 ( Table 2) .
Then we performed family-based association analysis between three polymorphic markers (C1758T in intron 6, C2666T in intron 7, and A745G in intron 14) and schizophrenia. The results of haplotype-based haplotype relative risk tests are shown in Table 3 . There was no significant association for any of the examined three polymorphisms in intron 6, 7, or 14.
Direct sequencing of genomic DNA in our subjects gave rise to some differences in the coding region, compared to the published cDNA sequence, 13 which are described in Figure 1 . Four of these differential nucleotides result in deduced amino acids different from those reported by Surratt et al. 13 There was no evidence for polymorphisms since all chromosomes (20 or more) examined were consistent in our Japanese subjects.
We determined exon/intron boundaries of the human SVMT gene, which enabled us to search for polymorphisms in the coding regions and neighboring intronic sequences. By using SSCP analysis, we detected two SNPs in the coding region; however, neither variation results in an amino acid change. In addition, we found four SNPs in introns. Since these intronic variations were located close to splicing sites, it is possible that some of these variations may have an effect on splicing. The family-based association analysis on 50 schizophrenic trios, however, did not reveal any significant association for either marker of Figure 1 Predicted cDNA and deduced amino acid sequences in the present study. First line: nucleotide number according to Surratt et al. 13 Second line: predicted cDNA sequence from our sequence data. Third line: deduced amino acid sequence. Underlined bold letters represent differential nucleotides and resultant amino acids compared to Surratt et al. 13 An asterisk represents the stop codon (tga). Five nucleotides are different from those described in the published cDNA sequence: C1010G, C1083A, C1166A, C1237G, and A1289T. Among them four differential nucleotides result in differences in deduced amino acids (Ser302Cys, Thr354Lys, Pro378Ala, and Asn395IIe).
C1758T polymorphism in intron 6, C2666T in intron 7, or A745G in intron 14, suggesting that these intronic polymorphisms do not play a major role for susceptibility to schizophrenia.
Our study has several limitations. The SSCP analysis does not necessarily detect all polymorphisms in the examined PCR products, although we performed the SSCP analysis on at least two conditions of gel electrophoresis for each target sequence. Furthermore, since the number of subjects examined in the SSCP analysis was 20, it is likely that we have failed to detect uncommon polymorphisms. The sample size (n = 50) of the family-based association study was not very large, leaving the possibility of false negative results. A larger sample size is required to detect potentially weak effects of the novel polymorphisms on susceptibility to schizophrenia.
Despite these limitations, our results suggest that there is no common polymorphism affecting the primary structure of the human SVMT protein. Furthermore, our family-based association analyses suggest none of the novel intronic variations to play a major role for susceptibility to schizophrenia. Although we obtained no evidence for the involvement of the SVMT gene in the pathogenesis of schizophrenia, the possibility remains that other as yet unknown polymorphisms in the promoter or intronic regions may have functional effects and play a role in the pathogenesis of the disease.
Methods

Determination of exon/intron boundaries
Since cDNA of the human SVMT gene is highly homologous to that of murine, 15 we predicted the localiz-ation of exon/intron boundaries and designed oligonucleotide primers accordingly, referring to the cDNA sequence of the human SVMT gene. 13 For PCR amplification of long DNA fragments, the long and accurate PCR (LA-PCR) method was employed by using DNA polymerase possessing 3Ј to 5Ј exonuclease activity (TaKaRa LA Taq). Obtained PCR products were sequenced by an autosequencer (ABI PRISM 377, Perkin Elmer, Chiba, Japan) to determine exon/intron boundaries and neighboring intronic sequences.
SSCP analysis
To detect novel polymorphisms in the coding region of the human SVMT gene, we employed PCR and single strand conformational polymorphism (SSCP) analysis, by using 17 sets of primers for PCR (Table 4) . For each target sequence, 20 patients with schizophrenia, who were biologically unrelated each other, were examined on at least two conditions of gel electrophoresis. When differential band patterns were observed on gel, PCR products were sequenced to determine the potential nucleotide change. SVMSS1F  GGACTGACGGAGCCCACTGCGGTG  172  SVMSS1R  CGTAGCTCTGGGGGCCTCCCTGCCTC  2  91-226  SVMSS2F  CTGGGGGACGGGAGAATGGGGGGT  271  SVMSS2R  GTAAGTGGAGTGCCGGGGAAGG  3  227-400  SVMSS3F1  GATCACCACCTTGCCATTCTGCTCTTATCCCC  234  SVMSS3R1  CACCATGTGCTGTGTGGCGGTCTGAT  3  392-569  SVMSS3F2  GTCACCGGGAATGCTACCAGAGACC  229  SVMSS3R2  CTCTTTGACTAAAGTAGTCTGCCCT  4  570-628  SVMSS4F  AAGGTCACATAGGAAGCACTGAG  249  SVMSS4R  CCCACACTCAGAAGGAAAACACCACACACT  5  629-712  SVMSS5F  TCTTGGACCCCCTCTCTCGGCA  140  SVMSS5R  CCTCACGAACTCACTCAGGCATTCC  6  713-805  SVMSS6F  GCCTGTTGACTATTTCTTTCCCTG  252  SVMSS6R  CAAAGTCTCCATGAAAGCAGG  7  806-895  SVMSS7F  TGTCCCCACTTTCTCTCCCTGC  144  SVMSS7R  ATGGCATGGCGCCCACGTGGACTCAC  8  894-949  SVMSS8F  CCGCCCTGGTACTCTTGGATGG  285  SVMSS8R  CAGCGTGGTTAGGGGTGTCC  9  940-1000  SVMSS9F  GTGCTGCTTCTGACCCGTGTTTTTTTC  118  SVMSS9R  CATCACCTCGCATTCCCCTGACT  10  1001-1096  SVMSS10F  TGTGCCTGGAAATGAGAGAGGAGGCAGAAGC  200  SVMSS10R  ATCAGAAGAGCCCACCCCAGTCC  11  1097-1175  SVMSS11F  CGGGGCTTCGTTTTATCTGCTCTC  384  SVMSS11R  CCCAGAAGAGCACAAAGCCACCTACCAAAAG  12  1176-1227  SVMSS12F  GTTGTTTCTGCCTTCGCTGTTAC  173  SVMSS12R  GGTCCCACTTGTCGAATGCCA  13  1228-1291  SVMSS13F  AGAAGGGAACAGGCATACCACGCTCAGA  248  SVMSS13R  CTACCAGAGGAAGAAGAACCC  14  1292-1411  SVMSS14F  CACTCTCTGATATTCGGCCCATTTTG  353  SVMSS14R  ATAGCACCACCAGCAGAAGGAC  15  1412-1545  SVMSS15F  ATGGATAACGTCTACTAAAATTG  305  SVMSS15R  GGAAGCTATCAGGAAGGCCATGCTAA  16  1546-1724  SVMSS16F  CAGTAGGTTAAAACCATCTTATC  278  SVMSS16R  ACCAGGGATGGATGGTATGACTAAGACAG   a Nucleotide numbering is according to Surratt et al 13 (GenBank accession L09118).
Molecular Psychiatry
Association analysis for detected polymorphisms
We performed family-based association analysis between three polymorphic markers (C1758T in intron 6, C2666T in intron 7, and A745G in intron 14) and schizophrenia. Subjects were 50 schizophrenics (31 men and 19 women; mean age (SD): 31 years (8)) and both parents. Consensus diagnosis by at least two psychiatrists was made for each schizophrenic proband, according to the DSM-IV criteria. 18 After describing the study, written informed consent to participate in the study was obtained from every subject. Statistical analysis was performed by the haplotype-based haplotype relative risk (HRR) approach, by using McNemar's test. 19 Among the six detected polymorphisms, two exonic variations were not examined for association with schizophrenia, since neither nucleotide substitution results in an amino acid change and thus neither was likely to have any functional effect on the SVMT protein. The other intronic variations may have some effect on splicing. Two polymorphisms in intron 7 (C2666T and C2683A) were tightly linked and one of these (C2666T) was selected for association analysis since this polymorphism gives rise to a restriction site (AccII). Thus we performed association analyses for the C1758T polymorphism in intron 6, C2666T in intron 7, and A745G in intron 14.
Genotyping was performed for the C1758T in intron 6 by PCR amplifications with primers SVMSS6F and SVMSS6R, followed by SSCP analysis. Genotyping for the C266T in intron 7 and the A745G in intron 14 was performed by PCR and digestion by restriction enzymes AccII and SnaBI, respectively (Table 2) .
